.png "Global Insight")
Monday, October 12, is one of the busiest days on India's market calendar in weeks: fresh inflation data, the unofficial start of IT earnings season, and a mega fundraising decision by India's largest drugmaker all land on the same day. Here is what investors and market watchers should track.
Inflation first: September CPI lands today
The consumer price index (CPI) inflation data for September is scheduled for release today, October 12, as reported by Outlook Money and NDTV Profit. August inflation stood at 4.82%. The number will be watched closely after the Reserve Bank of India raised the repo rate by 25 basis points to 5.50% in its October policy review and shifted toward calibrated tightening. One month's reading will not decide the RBI's next move on its own, but a hot print could harden expectations of more tightening, while a cooler number would give markets some breathing room. Wholesale price index (WPI) inflation follows on Wednesday, October 14, adding another data point on price pressures.
Earnings season kicks off with HCLTech
HCL Technologies' board meets today to approve its September-quarter results and consider an interim dividend, with numbers expected after market hours — making it the first big IT name to report, as noted by The Financial Economy and NDTV Profit. Investors will parse management commentary on demand conditions, revenue growth, and margins for clues on whether corporate earnings can sustain the market's recent recovery. The calendar gets busier through the week: Wipro and Persistent Systems report Thursday, Tech Mahindra on Friday, and HDFC Bank, ICICI Bank, and Axis Bank are all due later in the month, with Infosys on October 23. TCS will also stay in focus after its quarterly results helped lift IT sentiment on Friday, with the company highlighting growth in AI-related revenues.
Sun Pharma's ₹15,000 crore debt question
Sun Pharmaceutical Industries' board meets today to consider and approve issuing listed, rated, unsecured, redeemable non-convertible debentures (NCDs) worth up to ₹15,000 crore via private placement, in one or more tranches, according to the company's regulatory filing reported by TradingView and CNBC-TV18. The proposed issue has not happened yet — it needs board approval first. Media reports cited by Reuters suggest the debt sale could partly refinance a nearly $12 billion, 18-month bridge loan the company took to finance its acquisition of US healthcare firm Organon & Co. Investors will watch both the board's decision and how the market prices the country's largest drugmaker taking on more debt.
Stocks to watch and the global backdrop
Trent enters the week hot after jumping 13.1% on Friday on strong sales, as reported by Reuters via the Sunday Guardian — the question now is whether buying continues or traders book profits. Globally, US core CPI on October 14 and retail sales on October 15 will steer the Fed outlook and foreign fund flows into India; hotter US inflation typically pulls money out of emerging markets and weakens the rupee. Eurozone CPI follows on October 16.
This article is for informational purposes only and does not constitute investment advice.
Follow Global Insight for daily market explainers and business news.